WO2012105219A1 - Médicament stimulant l'effet thérapeutique d'anticorps - Google Patents

Médicament stimulant l'effet thérapeutique d'anticorps Download PDF

Info

Publication number
WO2012105219A1
WO2012105219A1 PCT/JP2012/000579 JP2012000579W WO2012105219A1 WO 2012105219 A1 WO2012105219 A1 WO 2012105219A1 JP 2012000579 W JP2012000579 W JP 2012000579W WO 2012105219 A1 WO2012105219 A1 WO 2012105219A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
tcp
cells
tricalcium phosphate
antibody therapy
Prior art date
Application number
PCT/JP2012/000579
Other languages
English (en)
Japanese (ja)
Inventor
丸山　宏二
満 高橋
雅裕 中川
靖人 秋山
秀衛 石井
錦雁 程
Original Assignee
オリンパス株式会社
静岡県
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリンパス株式会社, 静岡県 filed Critical オリンパス株式会社
Priority to JP2012555739A priority Critical patent/JP5990752B2/ja
Publication of WO2012105219A1 publication Critical patent/WO2012105219A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Au cours des récentes années, les anticorps médicaments se sont révélés présenter un intérêt en tant que traitement du cancer, mais, alors que dans certains cas l'activité des anticorps était trop faible pour donner des résultats thérapeutiques suffisants, dans d'autres cas, des dosages élevés se sont traduits en une charge économique trop élevée pour les patients. Pour cette raison, l'augmentation de l'activité immunitaire est devenue une question importante pour des médicaments de thérapie par anticorps, et le besoin d'un adjuvant de traitement par anticorps, capable de stimuler l'effet des anticorps médicaments et, par conséquent, de diminuer la quantité utilisée de ceux-ci, se fait sentir. S'il est possible de faire migrer et se rassembler des lymphocytes dans ou autour d'une tumeur, l'efficacité d'un anticorps médicament peut être encore améliorée. L'objectif de la présente invention concerne donc un médicament thérapeutique à adjuvant pour un traitement par anticorps sans danger et à faible coût, capable de stimuler l'effet des anticorps médicaments. L'implantation d'un corps dense de phosphate β-tricalcique (TCP) dans le corps fonctionne pour permettre une activité, une migration et une accumulation de cellules immunitaires. Les inventeurs ont découvert que l'effet thérapeutique d'anticorps médicaments peut être stimulé par l'utilisation de cette fonction, ce qui a conduit à l'amélioration de la présente invention.
PCT/JP2012/000579 2011-01-31 2012-01-30 Médicament stimulant l'effet thérapeutique d'anticorps WO2012105219A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012555739A JP5990752B2 (ja) 2011-01-31 2012-01-30 抗体療法の効果増強剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-018839 2011-01-31
JP2011018839 2011-01-31

Publications (1)

Publication Number Publication Date
WO2012105219A1 true WO2012105219A1 (fr) 2012-08-09

Family

ID=46602444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/000579 WO2012105219A1 (fr) 2011-01-31 2012-01-30 Médicament stimulant l'effet thérapeutique d'anticorps

Country Status (2)

Country Link
JP (1) JP5990752B2 (fr)
WO (1) WO2012105219A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007000637A (ja) * 2005-06-22 2007-01-11 Heraeus Kulzer Gmbh 成形可能なインプラント材料及びその使用
JP2007217307A (ja) * 2006-02-14 2007-08-30 Meiji Univ 薬剤送達用担体及びそれを利用した医薬
JP2009024014A (ja) * 2001-03-26 2009-02-05 Austin Research Inst 癌に対する抗体
JP2009525048A (ja) * 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
JP2009195739A (ja) * 2004-10-14 2009-09-03 Biomimetic Therapeutics Inc 血小板由来成長因子組成物及びそれらの使用方法
JP2010126434A (ja) * 2008-11-25 2010-06-10 Olympus Corp 癌細胞抑制剤および癌細胞抑制シート
JP2010540498A (ja) * 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH041122A (ja) * 1990-04-16 1992-01-06 Olympus Optical Co Ltd 薬物徐放材
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
EP1874342B1 (fr) * 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions et procédés destinés à l'immunothérapie du cancer
WO2007084661A2 (fr) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Glucane permettant d'améliorer une thérapie

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009024014A (ja) * 2001-03-26 2009-02-05 Austin Research Inst 癌に対する抗体
JP2009195739A (ja) * 2004-10-14 2009-09-03 Biomimetic Therapeutics Inc 血小板由来成長因子組成物及びそれらの使用方法
JP2007000637A (ja) * 2005-06-22 2007-01-11 Heraeus Kulzer Gmbh 成形可能なインプラント材料及びその使用
JP2009525048A (ja) * 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
JP2007217307A (ja) * 2006-02-14 2007-08-30 Meiji Univ 薬剤送達用担体及びそれを利用した医薬
JP2010540498A (ja) * 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
JP2010126434A (ja) * 2008-11-25 2010-06-10 Olympus Corp 癌細胞抑制剤および癌細胞抑制シート

Also Published As

Publication number Publication date
JPWO2012105219A1 (ja) 2014-07-03
JP5990752B2 (ja) 2016-09-14

Similar Documents

Publication Publication Date Title
JP2022535972A (ja) がん免疫療法の皮下投与のための組成物及び方法
Kanagavelu et al. In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation
Chang et al. Combined GM‐CSF and IL‐12 gene therapy synergistically suppresses the growth of orthotopic liver tumors
RU2689160C2 (ru) Противораковая таргетная иммунотерапия с применением il-12
CN106457001B (zh) 用于增强针对肿瘤的免疫应答的效力的方法
JP2013529187A (ja) ポリグルタミン酸ナノ粒子およびｃｄ４０アゴニストなどのポリペプチドを含む組成物
JP6245622B2 (ja) Ｉｌ−１８と分子標的抗体とを併用する癌治療薬
WO2021182573A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
CN113329790A (zh) 激酶抑制剂的结晶形式和盐形式
JP6629195B2 (ja) ウイルス免疫療法用の医薬組成物およびその使用
US20230263743A1 (en) Nanoparticle complex with defined sizes
WO2016119308A1 (fr) Préparation antitumorale et son procédé de préparation
JP2010220479A (ja) Ｎｋ細胞の培養方法及びｎｋ細胞の利用
KR102606179B1 (ko) 암의 치료를 위한 abx196을 포함하는 조합물
JP6082901B2 (ja) ワクチン・アジュバント
JP5990752B2 (ja) 抗体療法の効果増強剤
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
JP5966129B2 (ja) 免疫賦活剤
WO2021182571A1 (fr) Médicament pour le traitement et/ou la prévention du cancer
CN111225672B (zh) 甲羟戊酸通路抑制剂及其药物组合物
JP5828470B2 (ja) 免疫誘導剤
CN110639013A (zh) 一种以il-33为佐剂的hpv纳米疫苗组合物及其制备方法
CN110177552A (zh) 用于调节pd-1信号转导的组合物
WO2023080001A1 (fr) Composition pour le traitement d'une tumeur maligne solide, et kit pour le traitement d'une tumeur maligne solide
D’Souzaa Needle-Free Delivery of Ovarian Cancer Particulate Vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12742037

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012555739

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12742037

Country of ref document: EP

Kind code of ref document: A1